# [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

> **NCT07673341** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 22 (estimated)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **PROCEDURE:** Computed Tomography
- **RADIATION:** Fluorine F 18 Fluorthanatrace
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT07673341
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673341, "[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07673341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*